Skip to main content
Premium Trial:

Request an Annual Quote

Tm Posts Higher Q1 Losses Despite a 170-Percent Jump in Revenues

NEW YORK, May 15 (GenomeWeb News) - Tm Bioscience reported today higher losses in the first quarter despite a 170-percent jump in revenues.

 

Revenues in the quarter climbed to $2.9 million from $1.1 million a year earlier, reflecting a 140-percent surge in product sales. The company attributed the sales growth to the mid-2005 launch of its CFplus cystic fibrosis test by Genzyme and adoption of its expanded menu selections, primarily the Tag-It Ashkenazi Jewish Panel and the Tag-It CF70 reagents.

 

R&D spending remained flat year over year at $1 million.

 

Tm's first-quarter net loss rose to $4.1 million, or $.09 per share, from a year-ago loss of $3.4 million, or $.09 per share.

 

As of March 31, the company had cash, cash equivalents, and short-term investments totaling $7.5 million.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.